149 related articles for article (PubMed ID: 22200332)
1. In vitro and in vivo consideration of novel environmentally responsive ophthalmic drug delivery system.
Deshmukh PK; Gattani SG
Pharm Dev Technol; 2013; 18(4):950-6. PubMed ID: 22200332
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies.
Ranch KM; Maulvi FA; Naik MJ; Koli AR; Parikh RK; Shah DO
Int J Pharm; 2019 Jan; 554():264-275. PubMed ID: 30423418
[TBL] [Abstract][Full Text] [Related]
3. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time.
Destruel PL; Zeng N; Seguin J; Douat S; Rosa F; Brignole-Baudouin F; Dufaÿ S; Dufaÿ-Wojcicki A; Maury M; Mignet N; Boudy V
Int J Pharm; 2020 Jan; 574():118734. PubMed ID: 31705970
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery.
Wu H; Liu Z; Peng J; Li L; Li N; Li J; Pan H
Int J Pharm; 2011 May; 410(1-2):31-40. PubMed ID: 21397671
[TBL] [Abstract][Full Text] [Related]
5. A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen: in vitro and in vivo evaluation.
Zhu L; Ao J; Li P
Drug Des Devel Ther; 2015; 9():3943-9. PubMed ID: 26251573
[TBL] [Abstract][Full Text] [Related]
6. Thermoresponsive ophthalmic poloxamer/tween/carbopol in situ gels of a poorly water-soluble drug fluconazole: preparation and in vitro-in vivo evaluation.
Lihong W; Xin C; Yongxue G; Yiying B; Gang C
Drug Dev Ind Pharm; 2014 Oct; 40(10):1402-10. PubMed ID: 23944837
[TBL] [Abstract][Full Text] [Related]
7. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system.
Abraham S; Furtado S; Bharath S; Basavaraj BV; Deveswaran R; Madhavan V
Pak J Pharm Sci; 2009 Apr; 22(2):175-9. PubMed ID: 19339228
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release.
Rupenthal ID; Green CR; Alany RG
Int J Pharm; 2011 Jun; 411(1-2):69-77. PubMed ID: 21453762
[TBL] [Abstract][Full Text] [Related]
9. Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing.
Pathak MK; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2013 May; 39(5):780-90. PubMed ID: 22873799
[TBL] [Abstract][Full Text] [Related]
10. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery.
Gupta H; Velpandian T; Jain S
J Drug Target; 2010 Aug; 18(7):499-505. PubMed ID: 20055752
[TBL] [Abstract][Full Text] [Related]
11. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin.
Chavanpatil MD; Jain P; Chaudhari S; Shear R; Vavia PR
Int J Pharm; 2006 Jun; 316(1-2):86-92. PubMed ID: 16567072
[TBL] [Abstract][Full Text] [Related]
12. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels.
Asasutjarit R; Thanasanchokpibull S; Fuongfuchat A; Veeranondha S
Int J Pharm; 2011 Jun; 411(1-2):128-35. PubMed ID: 21459137
[TBL] [Abstract][Full Text] [Related]
13. A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation.
Sun J; Zhou Z
Drug Des Devel Ther; 2018; 12():383-389. PubMed ID: 29503531
[TBL] [Abstract][Full Text] [Related]
14. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system.
Srividya B; Cardoza RM; Amin PD
J Control Release; 2001 Jun; 73(2-3):205-11. PubMed ID: 11516498
[TBL] [Abstract][Full Text] [Related]
15. L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations.
Singh SR; Carreiro ST; Chu J; Prasanna G; Niesman MR; Collette Iii WW; Younis HS; Sartnurak S; Gukasyan HJ
J Pharm Pharmacol; 2009 Jun; 61(6):733-42. PubMed ID: 19505363
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan.
Fernández-Ferreiro A; González Barcia M; Gil-Martínez M; Vieites-Prado A; Lema I; Argibay B; Blanco Méndez J; Lamas MJ; Otero-Espinar FJ
Eur J Pharm Biopharm; 2015 Aug; 94():342-51. PubMed ID: 26079831
[TBL] [Abstract][Full Text] [Related]
17. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
Geethalakshmi A; Karki R; Jha SK; Venkatesh DP; Nikunj B
Curr Drug Deliv; 2012 Mar; 9(2):197-204. PubMed ID: 22283647
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
Rupenthal ID; Green CR; Alany RG
Int J Pharm; 2011 Jun; 411(1-2):78-85. PubMed ID: 21453763
[TBL] [Abstract][Full Text] [Related]
19. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.
Mehanna MM; Elmaradny HA; Samaha MW
Drug Dev Ind Pharm; 2010 Jan; 36(1):108-18. PubMed ID: 19656004
[TBL] [Abstract][Full Text] [Related]
20. Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.
Shastri DH; Prajapati ST; Patel LD
Curr Drug Deliv; 2010 Jul; 7(3):238-43. PubMed ID: 20497100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
